# A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

> **NCT00781911** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 43 (actual)

## Conditions studied

- Carcinoma
- Neuroendocrine Tumors

## Interventions

- **BIOLOGICAL:** Cixutumumab
- **DRUG:** depot octreotide

## Key facts

- **NCT ID:** NCT00781911
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2011-07
- **Final completion:** 2016-05
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00781911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00781911, "A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00781911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*